Caredx's heartcare multimodality service receives medicare coverage for heart transplant surveillance

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced medicare coverage for heartcare, a multimodality testing service that includes both allomap® heart and allosure® heart, in a given patient encounter, for heart transplant surveillance. coverage is effective april 1, 20.
CDNA Ratings Summary
CDNA Quant Ranking